These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1049 related articles for article (PubMed ID: 28583018)

  • 21. Blinatumomab-induced donor T-cell activation for post-stem cell transplant-relapsed acute CD19-positive biphenotypic leukemia.
    Alcharakh M; Yun S; Dong Y; Vincelette ND; Daud M; Manzoor S; Riaz IB; Anwer F
    Immunotherapy; 2016 Jul; 8(8):847-52. PubMed ID: 27381683
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blinatumomab for the treatment of adult acute lymphoblastic leukemia.
    Dahl J; Mace M; Kantarjian H; Jabbour E
    Drugs Today (Barc); 2015 Apr; 51(4):231-41. PubMed ID: 26020065
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blinatumomab: Bridging the Gap in Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia.
    Folan SA; Rexwinkle A; Autry J; Bryan JC
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S2-5. PubMed ID: 27521320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chimeric antigen receptor T cells for sustained remissions in leukemia.
    Maude SL; Frey N; Shaw PA; Aplenc R; Barrett DM; Bunin NJ; Chew A; Gonzalez VE; Zheng Z; Lacey SF; Mahnke YD; Melenhorst JJ; Rheingold SR; Shen A; Teachey DT; Levine BL; June CH; Porter DL; Grupp SA
    N Engl J Med; 2014 Oct; 371(16):1507-17. PubMed ID: 25317870
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia.
    Singh N; Frey NV; Grupp SA; Maude SL
    Curr Treat Options Oncol; 2016 Jun; 17(6):28. PubMed ID: 27098534
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia.
    Cai B; Guo M; Wang Y; Zhang Y; Yang J; Guo Y; Dai H; Yu C; Sun Q; Qiao J; Hu K; Zuo H; Dong Z; Zhang Z; Feng M; Li B; Sun Y; Liu T; Liu Z; Wang Y; Huang Y; Yao B; Han W; Ai H
    J Hematol Oncol; 2016 Nov; 9(1):131. PubMed ID: 27887660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.
    von Stackelberg A; Locatelli F; Zugmaier G; Handgretinger R; Trippett TM; Rizzari C; Bader P; O'Brien MM; Brethon B; Bhojwani D; Schlegel PG; Borkhardt A; Rheingold SR; Cooper TM; Zwaan CM; Barnette P; Messina C; Michel G; DuBois SG; Hu K; Zhu M; Whitlock JA; Gore L
    J Clin Oncol; 2016 Dec; 34(36):4381-4389. PubMed ID: 27998223
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blinatumomab as salvage therapy in patients with relapsed/refractory B-ALL who have failed/progressed after anti-CD19-CAR T therapy.
    Qi Y; Liu H; Li X; Shi Y; Mu J; Li J; Wang Y; Deng Q
    Ann Med; 2023 Dec; 55(1):2230888. PubMed ID: 37417690
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How to train your T cell: genetically engineered chimeric antigen receptor T cells versus bispecific T-cell engagers to target CD19 in B acute lymphoblastic leukemia.
    Ruella M; Gill S
    Expert Opin Biol Ther; 2015 Jun; 15(6):761-6. PubMed ID: 25640460
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blinatumomab for the treatment of acute lymphoblastic leukemia.
    Kaplan JB; Grischenko M; Giles FJ
    Invest New Drugs; 2015 Dec; 33(6):1271-9. PubMed ID: 26383529
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy.
    Goebeler ME; Bargou R
    Leuk Lymphoma; 2016 May; 57(5):1021-32. PubMed ID: 27050240
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia.
    Wu J; Fu J; Zhang M; Liu D
    J Hematol Oncol; 2015 Sep; 8():104. PubMed ID: 26337639
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic Leukemia.
    Pulte ED; Vallejo J; Przepiorka D; Nie L; Farrell AT; Goldberg KB; McKee AE; Pazdur R
    Oncologist; 2018 Nov; 23(11):1366-1371. PubMed ID: 30018129
    [TBL] [Abstract][Full Text] [Related]  

  • 34. T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts.
    Feucht J; Kayser S; Gorodezki D; Hamieh M; Döring M; Blaeschke F; Schlegel P; Bösmüller H; Quintanilla-Fend L; Ebinger M; Lang P; Handgretinger R; Feuchtinger T
    Oncotarget; 2016 Nov; 7(47):76902-76919. PubMed ID: 27708227
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current and future role of bispecific T-cell engagers in pediatric acute lymphoblastic leukemia.
    Algeri M; Del Bufalo F; Galaverna F; Locatelli F
    Expert Rev Hematol; 2018 Dec; 11(12):945-956. PubMed ID: 30358451
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chimeric antigen receptor T-cell therapy for ALL.
    Maude SL; Shpall EJ; Grupp SA
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):559-64. PubMed ID: 25696911
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-CD19 chimeric antigen receptors T cells for the treatment of relapsed or refractory E2A-PBX1 positive acute lymphoblastic leukemia: report of three cases.
    Zhang J; Yang F; Qiu HY; Wu Q; Kong DQ; Zhou J; Han Y; Wu DP
    Leuk Lymphoma; 2019 Jun; 60(6):1454-1461. PubMed ID: 30714847
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of Recurrent Acute Lymphoblastic Leukemia With T-Cell Engagement: CAR T, BiTEs, and Beyond.
    Park J
    J Natl Compr Canc Netw; 2019 Nov; 17(11.5):1448-1450. PubMed ID: 31766014
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase 1b study of blinatumomab in Japanese children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
    Horibe K; Morris JD; Tuglus CA; Dos Santos C; Kalabus J; Anderson A; Goto H; Ogawa C
    Int J Hematol; 2020 Aug; 112(2):223-233. PubMed ID: 32564243
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL.
    Myers RM; Taraseviciute A; Steinberg SM; Lamble AJ; Sheppard J; Yates B; Kovach AE; Wood B; Borowitz MJ; Stetler-Stevenson M; Yuan CM; Pillai V; Foley T; Chung P; Chen L; Lee DW; Annesley C; DiNofia A; Grupp SA; John S; Bhojwani D; Brown PA; Laetsch TW; Gore L; Gardner RA; Rheingold SR; Pulsipher MA; Shah NN
    J Clin Oncol; 2022 Mar; 40(9):932-944. PubMed ID: 34767461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 53.